TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06285045
Drug: Roujin Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 eligible participants with FMS of blood deficiency and liver depression syndrome were selected and randomly divided into treatment group(n=24)and control group(n=24). The treatment group was given Roujin Foumula 150mL,twice a day; The control group was given Roujin Foumula placebo 150mL,twice a day,the study period was 8 weeks. The evaluation points were 0 weeks,4 weeks,and 8 weeks of treatment,and follow-up to 12 weeks. To evaluate the effect changes before and after treatment,FIQR score、VAS score、PSQI score、BDI score and SF-36 PCS、MCS score were used as secondary efficacy evaluation indexes. SPSS23.0 was used to analyze the data.
Study: NCT00838591
Drug: MN-221
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo.
Study: NCT00838591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01699126
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin is an lipid lowering medication with anti-inflammatory effect.
Study: NCT02931838
Drug: Placebo for BMS-986165
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01489865
Drug: ABT-888 and mFOLFOX-6
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
Study: NCT04453826
Drug: Chemo-radiotherapy alone
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy
Study: NCT01866748
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.
Study: NCT01866748
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).
Study: NCT04001439
Drug: Experimental drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will recive 30 microbiota capsules intake preceded by bowel lavage by 4 liters macrogol solution. the capsules are developed by the services of JC Lagier.
Study: NCT00994825
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%
Study: NCT04525144
Drug: Tebonin Forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement: Gingko biloba EGb 761
Study: NCT00912782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one time per week for 3 weeks
Study: NCT05272397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg methylphenidate or placebo capsule - one per session (counterbalanced) approximately 1 week apart
Study: NCT01185938
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One oral single dose of rosuvastatin of 40 mg at admission and then 20 mg/day for 1 month.
Study: NCT01771146
Drug: FOLFIRINOX Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion
Study: NCT01978145
Drug: FSC
Normalized name: Dofscort 3%-1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods
Study: NCT01978145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
Study: NCT00003421
Drug: ABVD regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003421
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003421
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01646515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.~Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks
Study: NCT03657355
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching-placebo will be used.
Study: NCT04557657
Drug: Active bio Activa
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cement that release fluoride
Study: NCT04557657
Drug: Resin Cement
Normalized name: Quick Cure resin cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin Cement Convinonal
Study: NCT05546047
Drug: Acthar Gel 80 UNT/ML Injectable Solution
Normalized name: Acthar Gel 80 UNT/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow up and observation for 12 months off Acthar gel or Acthar gel and Tacrolimus
Study: NCT01774786
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive capecitabine 1000 mg/m\^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.
Study: NCT01774786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo (matched to pertuzumab) IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
Study: NCT01337219
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01898286
Drug: DiaPep277®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
Study: NCT01778075
Drug: Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
Study: NCT01778075
Drug: Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
Study: NCT01597648
Drug: GSK2838510
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
Study: NCT03375086
Drug: APX3330
Approvals — FDA: no, EMA: no, PMDA: no
Description: APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.
Study: NCT00682929
Drug: Oral THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.
Study: NCT00682929
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.
Study: NCT00682929
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
Study: NCT00610792
Drug: pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
Study: NCT00456755
Drug: Shi-Bi-Lin
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of treatment, dose of 1 g (two capsules), twice daily
Study: NCT06336395
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT01048242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT06336395
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral/ intrathecal/intravenous/subcutaneous
Study: NCT02479204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT-33441-matching placebo
Study: NCT01815424
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo BID for 16 weeks and then re-randomized into active groups
Study: NCT01815424
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 5mg BID for 52 weeks
Study: NCT01815424
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-690,550 10mg BID for 52 weeks
Study: NCT01092182
Drug: EPOCH-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
Study: NCT02081079
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV/SOF (90/400 mg) FDC tablet administered orally once daily
Study: NCT03942354
Drug: Directly observed therapy (DOT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy
Study: NCT04645407
Drug: Fuzheng Huayu tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time)
Study: NCT01282385
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance
Study: NCT01282385
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules with external characteristics similar to simvastatin administrated each 24 hours.
Study: NCT06336395
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous
Study: NCT06336395
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT01448889
Drug: 100% oxigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
Study: NCT01448889
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
Study: NCT06336395
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous
Study: NCT00230776
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03886220
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; Tablet
Study: NCT02664909
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03214159
Drug: NORVIR tablet 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: NORVIR Tablet is a generic product manufactured by AbbVie. NORVIR Tablet 100mg will be used as a comparator drug for the BE study.
Study: NCT02068222
Drug: ABT-530
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01897727
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03533699
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets with no active drug
Study: NCT01822080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo once daily by mouth
Study: NCT03724409
Drug: [90]Y-DOTATOC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-arterial infusion to the liver of \[90\]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.
Study: NCT02441933
Drug: Taxane
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.~* Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles~* Paclitaxel (80 mg/m2) IV weekly for 12 doses
Study: NCT01061723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Study: NCT00003730
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03837873
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg/m2, continuous i.v. on day 1-4
Study: NCT03837873
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750mg/m2, i.v. on day5
Study: NCT03245008
Drug: MT-5547-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection in pre-filled syringe
Study: NCT00654160
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00654160
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05276336
Drug: Pharmacology treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated with intranasal steroid and AH-1 according to ARIA WHO guideline 2008. Fluticasone furoate will be given twice a day with two sprays (100 µg) for each nostril for 2 weeks, then continue for once a day with two sprays (100 µg). Antihistamine H-1 is given 10 mg, once a day. Pharmacology treatment is given for 4 weeks, then intranasal steroid will be continued for another 4 weeks.
Study: NCT00699946
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
Study: NCT02410382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo
Study: NCT02507661
Drug: preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months
Normalized name: tricalcium phosphate
DrugBank: Calcium citrate (DB11093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02507661
Drug: no-preservation of alveolar ridge - 2 months
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02507661
Drug: preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months
Normalized name: tricalcium phosphate
DrugBank: Calcium citrate (DB11093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02507661
Drug: no-preservation of alveolar ridge - 4 months
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02507661
Drug: no-preservation of alveolar ridge - 9 months
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01067118
Drug: LINjeta U-100 Insulin
Normalized name: insulin isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors
Study: NCT03943576
Drug: GXCPC1
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×10\^6 or 4×10\^7 ADSCs in 3 mL saline. (allogeneic injection)
Study: NCT00634140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 4-6 weeks
Study: NCT02796833
Drug: SMOFlipid20%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03346187
Drug: Test drug(CKD-337)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-337(Atorvastatin calcium trihydrate 20mg+choline fenofibrate 178.8mg/capsule)
Study: NCT02807220
Drug: Imuneks 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
Study: NCT02444507
Drug: Nexium powder for injection and infusion 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
Study: NCT02444507
Drug: Esomelone Powder for Solution for Injection / Infusion 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
Study: NCT03953677
Drug: 5% glucose Infusion solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of placebo (5% glucose) at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
Study: NCT02836899
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
Study: NCT02253082
Drug: OctaplasLG®
Approvals — FDA: no, EMA: no, PMDA: no
Description: OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
Study: NCT01166789
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules daily, taken in morning and evening
Study: NCT02253095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00361972
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
Study: NCT00786305
Drug: ceftazidime and amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
Study: NCT00786305
Drug: ceftazidime and amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
Study: NCT06192472
Drug: 3% Polidcanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% Polidcanol
Study: NCT03815630
Drug: pd-1 and dc-cik cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total dose of 10ml Keytruda will be administered at day0, 60million DC cells and 1.5 billion CIK at day1, 1.5 billion CIK cells at day2, 1.5 billion CIK cells at day3 .
Study: NCT03768089
Drug: TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet for oral administration.
Study: NCT03768089
Drug: Placebo (matched to TEZ/IVA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to TEZ/IVA for oral administration.
Study: NCT03768089
Drug: Placebo (matched to IVA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to IVA for oral administration.
Study: NCT01534286
Drug: Theramine
Normalized name: Theramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theramine 2 capsules 3 times per day
Study: NCT01534286
Drug: Theramine- like placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theramine-like placebo capsules 2 three times daily
Study: NCT00480831
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00480831
Drug: PRO95780
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00003776
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003776
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003776
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00657137
Drug: apricoxib + lapatinib + capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: apricoxib: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert
Study: NCT00657137
Drug: placebo + lapatinib + capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert
Study: NCT03686930
Drug: Placebo (for FP-045 oral solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
Study: NCT01565408
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
Study: NCT04364815
Drug: Placebo plus standard preventive measures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet plus standard preventive measures as defined by PGH-HICU